Pages

Thursday, November 12, 2009

Upper Respiratory Tract Disease in Shelters

Dinnage, J.D., J.M. Scarlett, and J.R. Richards, Descriptive epidemiology of feline upper respiratory tract disease in an animal shelter. J Feline Med Surg, 2009. 11(10): p. 816-25.

Upper respiratory tract disease (URTD) is a common disease in cats and can spread quickly among cats residing in animal shelters. These infections cause suffering, consume vital personnel and financial resources, and limit adoptions. In a large urban shelter in the northeast United States, 531 kittens, 701 litters, and 2,203 adult cats were observed during their stays on a daily basis over a period of 50 weeks for signs of URTD. The median lengths of stay for adult cats and kittens were 5 and 4 days, respectively. Approximately 1/3 of the cats exhibited signs of infectious respiratory disease. Regardless of age group, the probability of developing URTD rose steadily with increasing time spent in the shelter. The probability of exhibiting signs remained low until day 6 and then rose steadily to where by day 14, the cumulative probabilities had risen to 84% (litters), 86% (individual kittens), and 80% (adult cats). In different categories, adult cats over 11 years of age had a significantly higher risk of URTD than younger cats. Neutered males cats had higher rates of URTD than spayed females, and purebred cats were at higher risk than ones of mixed breeding. Strays were more likely to have URTD than owner-surrendered cats. The study documented the strong association between the length of the residence in a shelter and the risk of developing URTD. The results suggest shelters should focus efforts and programs at minimizing the length of time cats spend in a shelter. [VT]
>> PubMed Abstract

Related articles:
Zicola, A., et al., Feline herpesvirus 1 and feline calicivirus infections in a heterogeneous cat population of a rescue shelter. J Feline Med Surg, 2009.
>> PubMed Abstract

Edwards, D.S., et al., Risk factors for time to diagnosis of feline upper respiratory tract disease in UK animal adoption shelters. Prev Vet Med, 2008. 87(3-4): p. 327-39.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter
Dinnage, J.D., J.M. Scarlett, and J.R. Richards, Descriptive epidemiology of feline upper respiratory tract disease in an animal shelter. J Feline Med Surg, 2009. 11(10): p. 816-25.

Upper respiratory tract disease (URTD) is a common disease in cats and can spread quickly among cats residing in animal shelters. These infections cause suffering, consume vital personnel and financial resources, and limit adoptions. In a large urban shelter in the northeast United States, 531 kittens, 701 litters, and 2,203 adult cats were observed during their stays on a daily basis over a period of 50 weeks for signs of URTD. The median lengths of stay for adult cats and kittens were 5 and 4 days, respectively. Approximately 1/3 of the cats exhibited signs of infectious respiratory disease. Regardless of age group, the probability of developing URTD rose steadily with increasing time spent in the shelter. The probability of exhibiting signs remained low until day 6 and then rose steadily to where by day 14, the cumulative probabilities had risen to 84% (litters), 86% (individual kittens), and 80% (adult cats). In different categories, adult cats over 11 years of age had a significantly higher risk of URTD than younger cats. Neutered males cats had higher rates of URTD than spayed females, and purebred cats were at higher risk than ones of mixed breeding. Strays were more likely to have URTD than owner-surrendered cats. The study documented the strong association between the length of the residence in a shelter and the risk of developing URTD. The results suggest shelters should focus efforts and programs at minimizing the length of time cats spend in a shelter. [VT]
>> PubMed Abstract

Related articles:
Zicola, A., et al., Feline herpesvirus 1 and feline calicivirus infections in a heterogeneous cat population of a rescue shelter. J Feline Med Surg, 2009.
>> PubMed Abstract

Edwards, D.S., et al., Risk factors for time to diagnosis of feline upper respiratory tract disease in UK animal adoption shelters. Prev Vet Med, 2008. 87(3-4): p. 327-39.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter
Read More


Monday, November 9, 2009

Treatment of Feline Hyperthyroidism with Carbimazole

Frenais, R., et al., Clinical efficacy and safety of a once-daily formulation of carbimazole in cats with hyperthyroidism. J Small Anim Pract, 2009. 50(10): p. 510-5.

Traditionally, medical treatment of feline hyperthyroidism has involved daily use of the azole drugs, methimazole or its pro-drug, carbimazole. Many cats require twice daily treatment with these drugs. A novel controlled-release formulation of carbimazole (Vidalta) has been developed by Intervet. These researchers evaluated the efficacy and safety of this new carbimazole formulation via a multi-center study of 44 client-owned cats with hyperthyroidism. Treatment was started at 15 mg/cat once daily, and dose was adjusted as required. Cats were followed for 53 weeks. The median dose over the study period was 10-15 mg/cat once daily. Clinical signs improved in almost all cats within 3 weeks after treatment was started. An increase in blood urea nitrogen (BUN) was noted in 25% of the cats, eosinophilia was noted in 20%, and lymphopenia in 16%. The researchers conclude that once daily administration of controlled-release carbimazole is effective with acceptable tolerance during short and long term treatment of feline hyperthyroidism. [SL]
>> PubMed Abstract

Related articles:
Frenais, R., S. Burgaud, and L.J.I. Horspool, Pharmacokinetics of controlled-release carbimazole tablets support once daily dosing in cats. Journal of Veterinary Pharmacology and Therapeutics, 2008. 31(3): p. 213-219.
>> PubMed Abstract

Trepanier, L.A., Medical management of hyperthyroidism. Clin Tech Small Anim Pract, 2006. 21(1): p. 22-8.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter
Frenais, R., et al., Clinical efficacy and safety of a once-daily formulation of carbimazole in cats with hyperthyroidism. J Small Anim Pract, 2009. 50(10): p. 510-5.

Traditionally, medical treatment of feline hyperthyroidism has involved daily use of the azole drugs, methimazole or its pro-drug, carbimazole. Many cats require twice daily treatment with these drugs. A novel controlled-release formulation of carbimazole (Vidalta) has been developed by Intervet. These researchers evaluated the efficacy and safety of this new carbimazole formulation via a multi-center study of 44 client-owned cats with hyperthyroidism. Treatment was started at 15 mg/cat once daily, and dose was adjusted as required. Cats were followed for 53 weeks. The median dose over the study period was 10-15 mg/cat once daily. Clinical signs improved in almost all cats within 3 weeks after treatment was started. An increase in blood urea nitrogen (BUN) was noted in 25% of the cats, eosinophilia was noted in 20%, and lymphopenia in 16%. The researchers conclude that once daily administration of controlled-release carbimazole is effective with acceptable tolerance during short and long term treatment of feline hyperthyroidism. [SL]
>> PubMed Abstract

Related articles:
Frenais, R., S. Burgaud, and L.J.I. Horspool, Pharmacokinetics of controlled-release carbimazole tablets support once daily dosing in cats. Journal of Veterinary Pharmacology and Therapeutics, 2008. 31(3): p. 213-219.
>> PubMed Abstract

Trepanier, L.A., Medical management of hyperthyroidism. Clin Tech Small Anim Pract, 2006. 21(1): p. 22-8.
>> PubMed Abstract

More on cat health: Winn Feline Foundation Library
Join us on Facebook
Follow us on Twitter
Read More